bioRxivImmunology
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, G.-G. Ortega-Delgado, M. Laporte, J. Niessl, L. Gokool, C. Morrisseau, P. Arlotto, J. Richard, , D. E. Kaufmann
Abstract
Spacing of the BNT162b2 mRNA doses beyond 3 weeks raised concerns about vaccine efficacy. We longitudinally analyzed B cell, T cell and humoral responses to two BNT162b2 mRNA doses administered 16 weeks apart in 53 SARS-CoV-2 naive and previously-infected donors. This regimen elicited robust RBD-specific B cell responses whose kinetics differed between cohorts, the second dose leading to increased magnitude in naive participants only. While boosting did not increase magnitude of CD4+ T cell responses further compared to the first dose, unsupervised clustering analyses of single-cell features revealed phenotypic and functional shifts over time and between cohorts. Integrated analysis showed longitudinal immune component-specific associations, with early Thelper responses post-first dose correlating with B cell responses after the second dose, and memory Thelper generated between doses correlating with CD8 T cell responses after boosting. Therefore, boosting elicits a robust cellular recall response after the 16-week interval, indicating functional immune memory.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: clustering
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity
A. Nicolas, G. Sannier, … D. E. Kaufmann·bioRxiv·Aug 3, 2022
- A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
- Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
C. Camara, D. Lozano-Ojalvo, … J. Ochando·bioRxiv·Mar 22, 2021
- Durability of immune responses to the BNT162b2 mRNA vaccine
M. Suthar, P. S Arunachalam, … P. Halfmann·bioRxiv·Sep 30, 2021
- Antibody and T cell memory immune response after two doses of the BNT162b2 mRNA vaccine in older adults with and without prior SARS-CoV-2 infection
J. Demaret, B. Corroyer-Simovic, … G. Lefevre·bioRxiv·Jul 8, 2021
- The BNT162b2 mRNA vaccine induces polyfunctional T cell responses with features of longevity.
G. Borsellino, G. Guerrera, … L. Battistini·Science ImmunologyPeer-reviewed·Dec 24, 2021